DCR / USDT

ZKC / BNB

ICP / ETH

ICP / BTC

ICP / EUR

ICP / FDUSD

ICP / TRY

ICP / USDT

ICP / USDC

HOLO / BNB

GIGGLE / USDT

GIGGLE / TRY

GIGGLE / USDC

EDEN / FDUSD

PEOPLE / BTC

XPL / USDC

XPL / USDT

XPL / TRY

DENT / ETH

TAO / TRY

KUNDAN EDIFICE LIMITED

SILLY MONKS ENTERTAIN LTD

3M INDIA LIMITED

KEYNOTE FIN SERV LTD.

QUADRANT FUTURE TEK LTD

HITACHI ENERGY INDIA LTD

THANGAMAYIL JEWELLERY LTD

SANGINITA CHEMICALS LTD

RENOL POLYCHEM LIMITED

ONELIFE CAP ADVISORS LTD

CAPITAL TRUST LTD

INDIAN EMULSIFERS LTD

JYOTI STRUCTURES LTD

FINEOTEX CHEMICAL LIMITED

JAY BEE LAMINATIONS LTD

ELEGANZ INTERIORS LIMITED

ITALIAN EDIBLES LIMITED

ZENITH DRUGS LIMITED

RELIANCE POWER LTD.

ADITYA VISION LIMITED

Click here to get full coverage on Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - LAmag

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients  LAmag

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - LAmag

Click here to get full coverage on Biocon Biologics eyes expansion in the US insulin market - livemint.com

Biocon Biologics eyes expansion in the US insulin market  livemint.com

Biocon Biologics eyes expansion in the US insulin market - livemint.com

Click here to get full coverage on Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - PR Newswire

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options  PR Newswire

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - PR Newswire

Click here to get full coverage on Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Biocon opens first US manufacturing facility in New Jersey  NJBIZ

Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Click here to get full coverage on Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ  Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Click here to get full coverage on Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says  Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Click here to get full coverage on Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites  Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Click here to get full coverage on Biocon clears US path for denosumab biosimilars - The Pharma Letter

Biocon clears US path for denosumab biosimilars  The Pharma Letter

Biocon clears US path for denosumab biosimilars - The Pharma Letter

Click here to get full coverage on Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara - BioSpace

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara  BioSpace

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara - BioSpace

Click here to get full coverage on Biocon Inaugurates First US Manufacturing Facility in Cranbury - New Jersey Business Magazine

Biocon Inaugurates First US Manufacturing Facility in Cranbury  New Jersey Business Magazine

Biocon Inaugurates First US Manufacturing Facility in Cranbury - New Jersey Business Magazine

Click here to get full coverage on Insulin Glargine Biocon: Biocon Partners with Civica to Launch in US - Deccan Herald

Insulin Glargine Biocon: Biocon Partners with Civica to Launch in US  Deccan Herald

Insulin Glargine Biocon: Biocon Partners with Civica to Launch in US - Deccan Herald

Click here to get full coverage on Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times

Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US  Ophthalmology Times

Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US - Ophthalmology Times

Click here to get full coverage on Biocon eyes generic semaglutide market for 2026 - Endpoints News

Biocon eyes generic semaglutide market for 2026  Endpoints News

Biocon eyes generic semaglutide market for 2026 - Endpoints News

Click here to get full coverage on Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars  Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Click here to get full coverage on Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey  PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Click here to get full coverage on Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives  PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Click here to get full coverage on Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States  PR Newswire

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire

Click here to get full coverage on Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio  PR Newswire

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire

Click here to get full coverage on Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. - PR Newswire

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.  PR Newswire

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. - PR Newswire

Click here to get full coverage on Biocon Biologics expands collaboration with Civica to supply affordable insulin in US - The Economic Times

Biocon Biologics expands collaboration with Civica to supply affordable insulin in US  The Economic Times

Biocon Biologics expands collaboration with Civica to supply affordable insulin in US - The Economic Times

Click here to get full coverage on Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States  GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Click here to get full coverage on Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea  Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Click here to get full coverage on Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% - Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%  Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% - Biocon

Click here to get full coverage on Biocon chief highlights Bengaluru ‘creaking’ infra - Times of India

Biocon chief highlights Bengaluru ‘creaking’ infra  Times of India

Biocon chief highlights Bengaluru ‘creaking’ infra - Times of India

Click here to get full coverage on Biocon’s Denosumab biosimilars gain EU marketing authorisation - Pharmaceutical Technology

Biocon’s Denosumab biosimilars gain EU marketing authorisation  Pharmaceutical Technology

Biocon’s Denosumab biosimilars gain EU marketing authorisation - Pharmaceutical Technology

Click here to get full coverage on Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States - PR Newswire

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States  PR Newswire

Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States - PR Newswire

Click here to get full coverage on Biocon Biologics Receives Health Canada Approval for - GlobeNewswire

Biocon Biologics Receives Health Canada Approval for  GlobeNewswire

Biocon Biologics Receives Health Canada Approval for - GlobeNewswire

Click here to get full coverage on Biocon gets 1 USFDA observation for Cranbury site - Medical Dialogues

Biocon gets 1 USFDA observation for Cranbury site  Medical Dialogues

Biocon gets 1 USFDA observation for Cranbury site - Medical Dialogues

Click here to get full coverage on Analysts recommend Alkem, Biocon, Indus Towers, Solar Industries; sell KEI Industries - CNBC TV18

Analysts recommend Alkem, Biocon, Indus Towers, Solar Industries; sell KEI Industries  CNBC TV18

Analysts recommend Alkem, Biocon, Indus Towers, Solar Industries; sell KEI Industries - CNBC TV18

Click here to get full coverage on Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis - PR Newswire

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis  PR Newswire

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis - PR Newswire

Click here to get full coverage on Biocon's new US facility clears key FDA hurdle - The New Indian Express

Biocon's new US facility clears key FDA hurdle  The New Indian Express

Biocon's new US facility clears key FDA hurdle - The New Indian Express

Click here to get full coverage on Biocon's New Jersey Facility Completes FDA Inspection with Single Observation - scanx.trade

Biocon's New Jersey Facility Completes FDA Inspection with Single Observation  scanx.trade

Biocon's New Jersey Facility Completes FDA Inspection with Single Observation - scanx.trade

Click here to get full coverage on Biocon’s antibacterial therapy gets tentative approval from FDA - ETPharma.com

Biocon’s antibacterial therapy gets tentative approval from FDA  ETPharma.com

Biocon’s antibacterial therapy gets tentative approval from FDA - ETPharma.com

Click here to get full coverage on Biocon Biologics Gets Health Canada Nod for Yesintek, a Biosimilar to Stelara - Medical Dialogues

Biocon Biologics Gets Health Canada Nod for Yesintek, a Biosimilar to Stelara  Medical Dialogues

Biocon Biologics Gets Health Canada Nod for Yesintek, a Biosimilar to Stelara - Medical Dialogues

Click here to get full coverage on Biocon founder Shaw harming Bengaluru’s interests with her social media posts, says Karnataka Dy CM Shivak - The Economic Times

Biocon founder Shaw harming Bengaluru’s interests with her social media posts, says Karnataka Dy CM Shivak  The Economic Times

Biocon founder Shaw harming Bengaluru’s interests with her social media posts, says Karnataka Dy CM Shivak - The Economic Times

Click here to get full coverage on Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV - The Economic Times

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV  The Economic Times

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV - The Economic Times

Click here to get full coverage on Biocon inks settlement, license pact with Amgen to market biosimilars in US - Business Standard

Biocon inks settlement, license pact with Amgen to market biosimilars in US  Business Standard

Biocon inks settlement, license pact with Amgen to market biosimilars in US - Business Standard

Click here to get full coverage on Biocon Buys Back Biologics OCDs from Goldman for $198.5 Mn - HDFC Sky

Biocon Buys Back Biologics OCDs from Goldman for $198.5 Mn  HDFC Sky

Biocon Buys Back Biologics OCDs from Goldman for $198.5 Mn - HDFC Sky

Click here to get full coverage on Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% - Biocon

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%  Biocon

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% - Biocon

Click here to get full coverage on Biocon gets stock bump after FDA approves interchangeable insulin biosimilar - FirstWord Pharma

Biocon gets stock bump after FDA approves interchangeable insulin biosimilar  FirstWord Pharma

Biocon gets stock bump after FDA approves interchangeable insulin biosimilar - FirstWord Pharma

Click here to get full coverage on Biocon to file weight-loss generic this Quarter, Launch expected by CY27: CEO - ETPharma.com

Biocon to file weight-loss generic this Quarter, Launch expected by CY27: CEO  ETPharma.com

Biocon to file weight-loss generic this Quarter, Launch expected by CY27: CEO - ETPharma.com

Click here to get full coverage on Biocon Biologics appoints Neelkanth Chandgothia as new Global Head - Corporate Finance - Medical Dialogues

Biocon Biologics appoints Neelkanth Chandgothia as new Global Head - Corporate Finance  Medical Dialogues

Biocon Biologics appoints Neelkanth Chandgothia as new Global Head - Corporate Finance - Medical Dialogues

Click here to get full coverage on 'We lack pride': Kiran Mazumdar-Shaw blasts Bengaluru garbage problem; Biocon chief stands firm after DK - Times of India

'We lack pride': Kiran Mazumdar-Shaw blasts Bengaluru garbage problem; Biocon chief stands firm after DK  Times of India

'We lack pride': Kiran Mazumdar-Shaw blasts Bengaluru garbage problem; Biocon chief stands firm after DK - Times of India

Click here to get full coverage on Biocon Biologics, Civica ink deal to launch low-cost insulin glargine in US - Moneycontrol

Biocon Biologics, Civica ink deal to launch low-cost insulin glargine in US  Moneycontrol

Biocon Biologics, Civica ink deal to launch low-cost insulin glargine in US - Moneycontrol

Click here to get full coverage on FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek - Center for Biosimilars

FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek  Center for Biosimilars

FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek - Center for Biosimilars

Click here to get full coverage on Biocon's Q3 revenue dips; banks on obesity drugs for future growth - Reuters

Biocon's Q3 revenue dips; banks on obesity drugs for future growth  Reuters

Biocon's Q3 revenue dips; banks on obesity drugs for future growth - Reuters

Click here to get full coverage on Biocon inaugurates first manufacturing facility in US - The Economic Times

Biocon inaugurates first manufacturing facility in US  The Economic Times

Biocon inaugurates first manufacturing facility in US - The Economic Times

Click here to get full coverage on Biocon's subsidiary get US FDA approval for diarrhea medication Rifaximin - Business Standard

Biocon's subsidiary get US FDA approval for diarrhea medication Rifaximin  Business Standard

Biocon's subsidiary get US FDA approval for diarrhea medication Rifaximin - Business Standard

Click here to get full coverage on Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options – Company Announcement - FT.com - Financial Times

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options – Company Announcement - FT.com  Financial Times

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options – Company Announcement - FT.com - Financial Times

Click here to get full coverage on After a $3.3 bn acquisition, is it finally time to look at Biocon? - The Indian Express

After a $3.3 bn acquisition, is it finally time to look at Biocon?  The Indian Express

After a $3.3 bn acquisition, is it finally time to look at Biocon? - The Indian Express

Click here to get full coverage on Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - PR Newswire Canada

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases  PR Newswire Canada

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - PR Newswire Canada

Click here to get full coverage on Biocon Biologics Bengaluru facility gets 5 USFDA observations - Medical Dialogues

Biocon Biologics Bengaluru facility gets 5 USFDA observations  Medical Dialogues

Biocon Biologics Bengaluru facility gets 5 USFDA observations - Medical Dialogues

Click here to get full coverage on Profit margins, US medicine supplies may get hit: Biocon - Times of India

Profit margins, US medicine supplies may get hit: Biocon  Times of India

Profit margins, US medicine supplies may get hit: Biocon - Times of India

Click here to get full coverage on Biocon Biologics, Amgen strike settlement, clear path for Bosaya, Aukelso in US - Medical Dialogues

Biocon Biologics, Amgen strike settlement, clear path for Bosaya, Aukelso in US  Medical Dialogues

BIOCON

Price Chart

Key Statistics

Technicals

About BIOCON

Latest News

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - LAmag

Biocon Biologics eyes expansion in the US insulin market - livemint.com

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - PR Newswire

Advanced Charts

Top Gainers

Top Losers